All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Larazotide Acetate (AT-1001)
For educational and research purposes only. Not medical advice.
Larazotide is the furthest-advanced tight junction regulator, in Phase III for celiac disease. Reduces symptoms and intestinal permeability in gluten-exposed celiac patients. Unique local-action mechanism with minimal systemic effects.
Best Time
Before each meal
Method
oral
Frequency
3x daily before meals
Half-life
Local GI action (not systemically absorbed)
Cycle Length
12 weeks per trial protocol
Storage
Room temperature. Stable in capsule form.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Med (New York, N.Y.) 2 (7) :864-883.e9 · 2021-07-09
Alimentary pharmacology & therapeutics 37 (2) :252-62 · 2013-01-01
Clinics and research in hepatology and gastroenterology 46 (1) :101782 · 2022-01-01
Clinical nutrition (Edinburgh, Scotland) 43 (6) :1240-1249 · 2024-06-01
Gastroenterology 148 (7) :1311-9.e6 · 2015-06-01
Mechanism of Action
Tight junction regulator that prevents zonulin-mediated opening of intestinal tight junctions. Reduces intestinal permeability ('leaky gut') without systemic absorption.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.